AstraZeneca Annual Report and Financial Statements Form 20-F Information 2003 79 13 Debtors 2003 2002 $m $m Amounts due within one year Trade debtors 3,260 2,701 Less: Amounts provided for doubtful debts 57 56 3,203 2,645 Deferred taxation Note 5 732 625 Other debtors 508 658 Prepayments and accrued income 1,093 519 5,536 4,447 Amounts due after more than one year Deferred taxation Note 5 165 226 Other debtors 32 16 Prepayments and accrued income 227 156 424 398 5,960 4,845 Figures include prepaid pension costs Note 29.
Provisions for doubtful debts 2003 2002 2001 $m $m $m Balance at beginning of year 56 42 39 Profit and loss account charge 8 11 4 Amounts utilised and other movements 7 3 1 Balance at end of year 57 56 42 14 Short term investments 2003 2002 $m $m Listed debt securities 3 144 Other listed investments 54 46 Investment securities 57 190 Fixed deposits 3,161 3,772 3,218 3,962 The Groups insurance subsidiaries hold cash and short term investments totalling $298m 2002 $173m, of which $195m 2002 $120m is required to meet insurance solvency requirements and which, as a result, is not readily available for the general purposes of the Group.
At 31 December 2002 $126m of short term investments shown above were committed as security against deferred payments due under a contractual obligation of the Group see Note 31.
The obligation was settled in 2003.
The market value of other listed investments was $140m 2002 $137m at the year end.
15 Short term borrowings and overdrafts 2003 2002 $m $m Bank borrowings Fixed securities 7 11 Unsecured 145 191 152 202
